May 2, 2018 / 11:50 AM / 3 months ago

BRIEF-Esperion Posts Qtrly Loss Per Share $1.73

May 2 (Reuters) - Esperion Therapeutics Inc:

* ESPERION PROVIDES BEMPEDOIC ACID FRANCHISE DEVELOPMENT PROGRAM UPDATES; REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

* ESPERION THERAPEUTICS INC - EXPECTS FULL-YEAR 2018 NET CASH USED IN OPERATING ACTIVITIES TO BE APPROXIMATELY $135 TO $145 MILLION

* ESPERION THERAPEUTICS - ESTIMATES THAT CURRENT CASH RESOURCES ARE SUFFICIENT TO FUND OPERATIONS THROUGH Q1 OF 2020

* ESPERION THERAPEUTICS INC - EXPECTS CASH AND CASH EQUIVALENTS AND INVESTMENT SECURITIES TO BE APPROXIMATELY $130 TO $140 MILLION AT DECEMBER 31, 2018

* ESPERION THERAPEUTICS INC QTRLY LOSS PER SHARE $1.73 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below